Home  >  Clinical Trials

Clinical Trials

Skin Cancer Research – Clinical Trials

Research into new ways of treating skin cancer is going on all the time. When a new treatment is being developed, it goes through various stages of research. To begin with it will be looked at in the laboratory, and sometimes tested on cancer cells in a test tube. If the treatment seems as though it might be useful in treating cancer, it is then given to patients in research studies. These early studies are called phase 1 trials.

If early studies suggest that a new treatment may be both safe and effective, further trials (phases 2 and 3) are done to answer these questions:

  • Is it better than existing treatments?
  • Does it have extra benefit when given together with existing treatments?
  • How does it compare with the current best standard treatments?

You may be asked to take part in a research trial. There can be many benefits in doing this. You will be helping to improve knowledge about cancer and the development of new treatments. You will also be carefully monitored during and after the study.

They aim to:

  • find a safe dose
  • see what side effects the therapy may cause
  • identify which cancers it might be used to treat

It is important to bear in mind that some treatments that look promising at first are often later found not to be as good as existing treatments, or to have side effects that outweigh any benefits.

As part of research you may be asked by your doctors for permission to store some of the samples of your cancer or blood, so that they can be used as part of trials to find the causes of cancer.

 

Published Skin Cancer Research Studies at Norfolk & Norwich University Hospital
(Last Five Years)

Lo MC, Garioch J, Moncrieff MD. Sequencing in management of in-transit melanoma metastasis: Diphencyprone versus isolate limb infusion. J Plast Reconstr Aesthet Surg. 2020 Mar 17. pii: S1748-6815(20)30133-9. doi: 10.1016/j.bjps.2020.03.007. PubMed PMID: 32245735.

Moncrieff MD, O’Leary FM, Beadsmoore CJ, Pawaroo D, Heaton MJ, Isaksson K, Olofsson Bagge R. Effect of delay between nuclear medicine scanning and sentinel node biopsy on outcome in patients with cutaneous melanoma. Br J Surg. 2020 Feb 19. doi: 10.1002/bjs.11460. PubMed PMID: 32077090.

Robinson AV, Keeble C, Lo MCI, Thornton O, Peach H, Moncrieff MDS, Dewar DJ, Wade RG. The neutrophil-lymphocyte ratio and locoregional melanoma: a multicentre cohort study. Cancer Immunol Immunother. 2020 Apr;69(4):559-568. doi: 10.1007/s00262-019-02478-7. Epub 2020 Jan 23. PubMed PMID: 31974724;

Lo MC, Heaton MJ, Snelling A, Moncrieff MD. Reconstructive burden and financial implications of wider excision margins for invasive primary cutaneous melanoma. J Plast Reconstr Aesthet Surg. 2020 Feb;73(2):313-318. doi:10.1016/j.bjps.2019.09.035. Epub 2019 Oct 2. PubMed PMID: 31680028.

Lo MCI, White SH, Nunney I, Skrypniuk J, Heaton MJ, Moncrieff MDS. A feasibility study of indocyanine green fluorescence mapping for sentinel lymph node detection in cutaneous melanoma. J Plast Reconstr Aesthet Surg. 2019 Jan;72(1):137-171. doi: 10.1016/j.bjps.2018.10.017. Epub 2018 Nov 2. PubMed PMID:30467004.

O’Leary FM, Beadsmoore CJ, Pawaroo D, Skrypniuk J, Heaton MJ, Moncrieff MD. Survival outcomes and interval between lymphoscintigraphy and SLNB in cutaneous melanoma- findings of a large prospective cohort study. Eur J Surg Oncol. 2018 Nov;44(11):1768-1772. doi: 10.1016/j.ejso.2018.06.011.  PubMedID: 30343702.

Wade RG, Robinson AV, Lo MCI, Keeble C, Marples M, Dewar DJ, Moncrieff MDS, Peach H. Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study. Ann Surg Oncol. 2018 Oct;25(11):3341-3349. doi: 10.1245/s10434-018-6660-x. Epub 2018 Jul 31. PubMedID: 30066226;

Moncrieff MD, Gyorki D, Saw R, Spillane AJ, Thompson JF, Peach H, Oudit D, Geh J, Dziewulski P, Wilson E, Matteucci P, Pritchard-Jones R, Olofsson Bagge R, Wright FC, Crampton N, Cassell O, Jallali N, Berger A, Kelly J, Hamilton S, Durrani A, Lo S, Paton E, Henderson MA. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Ann Surg Oncol. 2018 Sep;25(9):2541-2549. doi: 10.1245/s10434-018-6470-1. Epub 2018 May 30. Erratum in: Ann Surg Oncol. 2018 Jun 26;:. Thompson JF [added]. PubMedID: 29850955;

Swanson DL, Venneugues RV, Vicencio SQ, Garioch J, Biryulina M, Ryzhikov G, Hamre B, Zhao L, Castellana FS, Stamnes K, Stamnes JJ. Optical transfer diagnosis differentiating benign and malignant pigmented lesions in a simulated primary care practice. Br J Dermatol. 2018 Feb;178(2):541-546. doi: 10.1111/bjd.15898. Epub 2018 Jan 20. PubMed PMID: 28832952.

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB,
Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210. PubMedID: 28591523;

Thomson CH, Cassell O, Peach H, Holloway S, Garioch J, Moncrieff M. Neuropathic pain and quality of life after wide local excision and sentinel lymph node biopsy for melanoma: a multicentre study. Melanoma Res. 2017 Apr;27(2):121-125. doi: 10.1097/CMR.0000000000000321. PubMedID: 28253208.

Lo MCI, Maraka J, Garioch J, John WG, Moncrieff M. Monitoring vitamin D in the patient with melanoma: impact of sun avoidance on vitamin D levels of patients with melanoma at a U.K. tertiary-referral melanoma service. Br J Dermatol. 2017 Jul;177(1):282-283. doi: 10.1111/bjd.15062. Epub 2017 Jun 5. PubMedID: 27639181.

Lo MC, Paterson A, Maraka J, Clark R, Goodwill J, Nobes J, Garioch J, Moncrieff M, Rytina E, Igali L. A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma. Br J Cancer. 2016 Jul 12;115(2):223-7. doi:10.1038/bjc.2016.106. Epub 2016 Jun 23. PubMedID: 27336602;

Anninga B, White SH, Moncrieff M, Dziewulski P, L C Geh J, Klaase J, Garmo H, Castro F, Pinder S, Pankhurst QA, Hall-Craggs MA, Douek M; MELAMAG Multicentre Trialists Group. Magnetic Technique for Sentinel Lymph Node Biopsy in Melanoma: The MELAMAG Trial. Ann Surg Oncol. 2016 Jun;23(6):2070-8. doi:10.1245/s10434-016-5113-7. Epub 2016 Feb 19. PubMedID: 26895751.

Moncrieff M, Fadhil M, Garioch J. Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience. Br J Dermatol. 2016 May;174(5):1141-2. doi: 10.1111/bjd.14314. Epub 2016 Feb 11. PubMedID: 26598951.

Ridha H, Garioch JJ, Tan EK, Heaton MJ, Igali L, Moncrieff MD. Intraoperative use of Mohs’ surgery for the resection of major cutaneous head and neck cancer under general anaesthetic: Initial experiences, efficiency and outcomes. J Plast Reconstr Aesthet Surg. 2015 Dec;68(12):1706-12. doi: 10.1016/j.bjps.2015.08.004.
Epub 2015 Aug 19. PubMedID: 26342654.

Moncrieff MD, Shah AK, Igali L, Garioch JJ. False-negative rate of intraoperative frozen section margin analysis for complex head and neck non-melanoma skin cancer excisions. Clin Exp Dermatol. 2015 Dec;40(8):834-8. doi: 10.1111/ced.12743. Epub 2015 Aug 19. PubMedID: 26290360.

Winstanley JB, Young TE, Boyle FM, Bergenmar M, Bottomley A, Burmeister B, Campana LG, Garioch JJ, King M, Nikolic DV, van de Poll-Franse LV, Saw R, Thompson JF, White EG; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group. Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module.  Melanoma Res. 2015 Feb;25(1):47-58. doi: 10.1097/CMR.0000000000000122. PubMed PMID: 25325247.